CancerTYPE ID is a proprietary molecular cancer classifier used to identify unknown or unclear tumor types and subtypes in patients with metastatic cancer. When ordered through NeoGenomics, classification with CancerTYPE ID is followed by tumor profiling for actionable biomarkers using the NeoTYPE® Cancer Profile most appropriate for the tumor type identified by Cancer TYPE ID.† Tech-only options for FISH and IHC within the NeoTYPE Cancer Profile are available.
CancerTYPE ID is performed, reported and billed separately by Biotheranostics, Inc., an independent CLIA-licensed and CAP-accredited reference laboratory. The test uses quantitative RT-PCR to measure the expression of 92 genes in the patient’s specimen and classifies the tumor by matching the gene expression profile to a database of more than 2000 known tumor types and subtypes. Using this technology, CancerTYPE ID can identify 50 different tumor types and subtypes, covering >95% of all solid tumors based on incidence.1 The test reports a main cancer type with the highest probability, as well as a list of tumor types that may be ruled out with 95% confidence.
†CancerTYPE ID may be ordered as a stand-alone test directly from Biotheranostics, Inc. Please see www.cancertypeid.com.
For difficult-to-diagnose metastatic cancer cases, CancerTYPE ID provides important tumor type information to resolve diagnostic dilemmas. It can help narrow a differential diagnosis so that clients may confidently report a single final diagnosis2 and efficiently identify targetable mutations in genes pre-selected for their known impact in that tumor type.
Please see our Test Spotlight page for more information about CancerTYPE ID’s utility, performance, additional references, and which tumor-specific NeoTYPE Cancer Profile will be paired with each potential CancerTYPE ID result when ordered from NeoGenomics.
- FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixative.
Testing may be ordered through NeoGenomics via our online test order system or by using the current NGS Solid Tumor Pathology Requisition.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.
Approximately 21-23 days. CancerTYPE ID results can be expected 7-9 calendar days after receipt of specimen and required information into Biotheranostics’ laboratory. NeoTYPE Cancer Profile results follow approximately 14 days later.
- Erlander M et al. J Mol Diagn. 2011;13(5):493-503.
- Thomas SP et al. J Clin Oncol. 2015;33 (suppl 3; abst 249).